NEWS RELEASE

Acorda Therapeutics Named One of the Best Places to Work For in New York 2015

4/22/2015

Westchester-based biotechnology company ranked in top 10 for fifth consecutive year

ARDSLEY, N.Y.--(BUSINESS WIRE)-- Biotechnology leader Acorda Therapeutics, Inc. (Nasdaq:ACOR) has been named one of the best companies to work for in New York, based on an independent survey by the Best Companies Group (BCG). Acorda was named to the list for the fifth consecutive year.

Acorda was ranked third among this year's list of large employers, defined as employing more than 250 people. The rankings are determined by feedback from employees about company culture, benefits and overall job satisfaction.

"It's gratifying to be recognized as one of the best places to work in New York, especially when that recognition is based on feedback from Acorda's own associates," said Ron Cohen, M.D., Acorda's President and CEO. "A key contributor to our success is the company's vibrant culture, which emphasizes teamwork, integrity and fun. Acordans also share a deeply held sense of mission, to develop life-changing therapies for people with neurological disorders. These features make Acorda a great place to build a career."

"The dedication of our associates is exemplified by their having brought AMPYRA to market; AMPYRA is a unique medication that improves walking for people with multiple sclerosis. This spirit of innovation has also allowed us to build one of the most exciting neurology pipelines in the industry, with the potential to improve the lives of people with conditions such as Parkinson's disease, stroke, epilepsy, multiple sclerosis and heart failure," continued Cohen.

The Best Places to Work survey was conducted by BCG, an independent company that manages Best Places to Work programs on state, regional and national levels. The award is a partnership of the New York State Society for Human Resource Management, the Business Council of New York, BCG and Journal Multimedia Corporation.

About Acorda Therapeutics

Founded in 1995, **Acorda Therapeutics** is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

Acorda markets three FDA-approved therapies, including **AMPYRA®** (dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS), as demonstrated by an increase in walking speed. The Company has one of the leading pipelines in the industry of novel neurological therapies. Acorda is currently developing a number of clinical and preclinical stage therapies. This pipeline addresses a range of disorders including post-stroke walking deficits, Parkinson's disease, epilepsy, neuropathic pain, heart failure, MS and spinal cord injury.

For more information, please visit the Company's website at: **www.acorda.com**.

AMPYRA (dalfampridine) Important Safety Information

Do not take AMPYRA if you

• have ever had a seizure,

• have certain types of kidney problems, or

• are allergic to dalfampridine (4-aminopyridine), the active ingredient in AMPYRA.

Take AMPYRA exactly as prescribed by your doctor.

Before taking AMPYRA, tell your doctor if you

• have kidney problems or any other medical conditions

• are taking compounded 4-aminopyridine

• are pregnant or plan to become pregnant. It is not known if AMPYRA will harm your unborn baby.

• are breastfeeding or plan to breastfeed. It is not known if AMPYRA passes into your breast milk. You and your doctor should decide if you will take AMPYRA or breastfeed. You should not do both.

• are taking any other medicines.

Stop taking AMPYRA and call your doctor right away if you have a seizure while taking AMPYRA. You could have a seizure even if you never had a seizure before. Your chance of having a seizure is higher if you take too much

AMPYRA or if your kidneys have a mild decrease of function, which is common after age 50. Your doctor may do a blood test to check how well your kidneys are working before you start AMPYRA.

AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same.

AMPYRA may cause serious side effects, including

• severe allergic reactions. Stop taking AMPYRA and call your doctor right away or get emergency medical help if you have shortness of breath or trouble breathing, swelling of your throat or tongue, or hives;

• kidney or bladder infections.

The most common adverse events for AMPYRA in MS patients were urinary tract infection, trouble sleeping, dizziness, headache, nausea, weakness, back pain, problems with balance, multiple sclerosis relapse, burning, tingling, or itching of your skin, irritation in your nose and throat, constipation, indigestion, and pain in your throat.

Please see the Patient Medication Guide at **https://ampyra.com/medication-guide.pdf**.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit **http://www.fda.gov/MedWatch**, or call 1-800-FDA-1088.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including the ability to realize the benefits anticipated from the Civitas transaction and to successfully integrate Civitas' operations into our operations; our ability to successfully market and sell Ampyra in the U.S.; third party payers (including governmental agencies) may not reimburse for the use of Ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra or from our other research and development programs, including CVT-301, Plumiaz, or any other acquired or in-licensed programs; we may not be able to complete development of, obtain regulatory approval for, or successfully market CVT-301, Plumiaz, or any other products under development; we may need to raise additional funds to finance our expanded operations and may not be able to do so on acceptable terms; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of or to successfully market Fampyra outside of the U.S. and our dependence on our collaboration partner Biogen in connection therewith; competition; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of

our products; and, failure to comply with regulatory requirements could result in adverse action by regulatory agencies.

These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this release are made only as of the date hereof, and Acorda disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this release.

Source: Acorda Therapeutics, Inc.

Acorda Therapeutics

Jeff Macdonald, 914-326-5232

jmacdonald@acorda.com